From The Source

NHMRC: Investigator Grants 2026 forecast opportunity
WorkCover Queensland: Standing Offer Arrangement for Medical and Allied Health Services
WA: North Metropolitan Health Service: Supply, Delivery, Installation and Commissioning of Closed Vial Dose Dispensers
AIHW: Pharmaceutical Benefits Scheme prescriptions: monthly data
AIHW: Medicare Benefits Scheme funded services: monthly data
Amplia Therapeutics: ENCOURAGING UPDATED DATA FROM PANCREATIC CANCER TRIAL
DoHAC: Upcoming Changes to Bulk Billing Incentives in General Practice
Victorian Health Association: Federal Budget primary care focus welcomed, with some missed opportunities
American pharmaceutical boss does not support tariffs on Australian medicines
Better access to palliative care – Australians call for action – Palliative Care Australia
PHA/Mandala: Reducing out-of-pocket costs for Australian healthcare consumers
NNZ-2591, a Synthetic IGF-1 Metabolite Analog: Phase 2 Clinical Trial Resultsfor Children and Adolescents With Pitt Hopkins Syndrome

08 February 2024

Bioxyne subsidiary gets nod to manufacture cannabis, psilocybin and MDMA

1 minute read

Members Pharma/Biotech

Staff Writers

Breathe Life Sciences wants to be the leading supplier to clinical trials and authorised prescribers by 2025.

This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.

End of content

No more pages to load

New Member Registration Existing member? log in.

You have selected the Trial membership level. change

This membership level is Free

Account Information

Email Address

Password

Confirm Password

First Name

Last Name

What part of the health sector do you work in?

Organisation

Job Title

AHPRA Number

Newsletter Frequency

Daily News

Full Name LEAVE THIS BLANK

Total to pay: Free

All payments subject to GST. If you are an international customer, contact us.

Processing... This can take up to 15 seconds.
You will be redirected once complete.

Bioxyne subsidiary gets nod to manufacture cannabis, psilocybin and MDMA

Is our digital health agenda getting too big not to fail?

Butler bullish on UCCs, despite gaping holes in new evaluation

From scope of practice to a DOGE brushfire, the sector responds

NHMRC: Investigator Grants 2026 forecast opportunity

WorkCover Queensland: Standing Offer Arrangement for Medical and Allied Health Services

WA: North Metropolitan Health Service: Supply, Delivery, Installation and Commissioning of Closed Vial Dose Dispensers

AIHW: Pharmaceutical Benefits Scheme prescriptions: monthly data

AIHW: Medicare Benefits Scheme funded services: monthly data

Amplia Therapeutics: ENCOURAGING UPDATED DATA FROM PANCREATIC CANCER TRIAL

DoHAC: Upcoming Changes to Bulk Billing Incentives in General Practice

Victorian Health Association: Federal Budget primary care focus welcomed, with some missed opportunities

American pharmaceutical boss does not support tariffs on Australian medicines

Better access to palliative care – Australians call for action – Palliative Care Australia

PHA/Mandala: Reducing out-of-pocket costs for Australian healthcare consumers

NNZ-2591, a Synthetic IGF-1 Metabolite Analog: Phase 2 Clinical Trial Resultsfor Children and Adolescents With Pitt Hopkins Syndrome

Data Retention Review – PHA Submission

National Health Practitioner Ombudsman: monthly report

Services Australia: Monthly and Quarterly Standard Reports

New Member Registration Existing member? log in.

Account Information

Payment Information We accept all major credit cards

Log in

New Member Registration Existing member? log in.

Account Information

Payment Information We accept all major credit cards